Effect of Probiotic Supplementation on the Immune System in Patients With Ulcerative Colitis in Amman, Jordan
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
Ulcerative colitis (UC) is a chronic Inflammatory bowel disease (IBD) that most likely
results from the interaction between various environmental and genetic factors. Using
probiotics as an adjunct to medical therapy might be useful in the treatment of UC and
improving the symptoms of the disease. The result of studies that investigate the role of
Probiotics supplementation in improving the inflammatory response, immune response and life
quality of patients with the UC is not conclusive. So, this study aimed to study the effect
of probiotics on the response of inflammatory markers, immune response, and quality of life
in patients with UC.
An interventional double-blind randomized clinical trial (RCT) design will be used in this
study. Forty patients will be recruited and randomly assigned to the placebo group (n=20) to
receive 3 times a day placebo capsules; and probiotics group (n=20), to receive 3 times a day
probiotic supplement. The demographic data, anthropometric measurements, IBD Quality of Life
Questionnaire and blood samples will be collected at baseline and after 6 weeks of follow up.
Interleukin-6, interleukin-1,interleukin-10 IL-10, C-reactive protein, tumor necrosis
factor-alpha and complete blood count (CBC) will be measured.
The results will approve or disapprove the beneficial effect of using probiotics as adjuvant
therapy for UC patients to raise the immune system as well as improving their quality of
life.